Erectile Dysfunction News and Research RSS Feed - Erectile Dysfunction News and Research

Erectile Dysfunction (ED) is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.
Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. [More]
Prodromal symptoms precede PD by up to a decade

Prodromal symptoms precede PD by up to a decade

Many prodromal symptoms of Parkinson’s disease appear long before a clinical diagnosis is made, shows a large study of patients in primary care. [More]
Mediterranean diet improves cardiovascular performance in patients with erectile dysfunction

Mediterranean diet improves cardiovascular performance in patients with erectile dysfunction

The Mediterranean diet is linked to improved cardiovascular performance in patients with erectile dysfunction, according to research presented at EuroEcho-Imaging 2014 by Dr Athanasios Angelis from Greece. Patients with erectile dysfunction who had poor adherence to the Mediterranean diet had more vascular and cardiac damage. [More]
Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects. [More]
Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Long-term T therapy in hypogonadal men is safe, does not increase PCa risk, study finds

Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data. [More]
Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014. [More]
Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

Men with BPH need to discuss 'male orgasmic dysfunction' with doctors prior to any treatment

NeoTract, Inc., today welcomes the publication of a paper in the British Journal of Urology International which calls for men suffering from enlarged prostate to discuss with their doctors the likely impact of treatment options on their sexual function. Most procedures and many medications can cause sexual dysfunction. Clinical studies show that treatment with the UroLift system has not been associated with any new onset of sustained ejaculatory or erectile dysfunction. [More]
Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. [More]
Nonmotor predictors of Parkinson’s dementia revealed

Nonmotor predictors of Parkinson’s dementia revealed

Researchers have identified nonmotor and nondopaminergic motor features that predict incident dementia in patients with Parkinson’s disease. [More]
Emo Capital, I-Omni partner to develop new compression wear clothing line

Emo Capital, I-Omni partner to develop new compression wear clothing line

Emo Capital Corp. is pleased to announce that a memorandum of understanding (MOU) was signed with I-Omni Co. Ltd. of Seoul, South Korea . [More]
Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International enters into definitive agreement to acquire Auxilium Pharmaceuticals

Endo International plc and Auxilium Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. [More]
Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects. [More]
Testosterone therapy raises risk of prostate tumors in rats

Testosterone therapy raises risk of prostate tumors in rats

A researcher who found that testosterone raised the risk of prostate tumors and exacerbated the effects of carcinogenic chemical exposure in rats is urging caution in prescribing testosterone therapy to men who have not been diagnosed with hypogonadism, according to a new study published in the Endocrine Society's journal Endocrinology. [More]
Study uncovers new pathway for treating high blood pressure, heart failure

Study uncovers new pathway for treating high blood pressure, heart failure

New research by scientists at the University of Maryland School of Medicine and the Ottawa Heart Institute has uncovered a new pathway by which the brain uses an unusual steroid to control blood pressure. [More]

Drug and device news: Study questions medical devices' safety evidence

Elsewhere, The Associated Press reports on a new advertising approach for Viagra -- a TV commercial that targets women. [More]
ED more prevalent than previously thought

ED more prevalent than previously thought

Specialists in treatment of erectile dysfunction recognize that ED is more prevalent than previously recognized. [More]
Experts share tips on prevention of prostate cancer

Experts share tips on prevention of prostate cancer

Prostate cancer is the second leading cause of cancer death in American men. One in seven men will be diagnosed with prostate cancer and 233,000 new cases are diagnosed annually. [More]
White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

White pill may help scientists learn why patients with cystic fibrosis have less exercise capacity

A little white pill may help scientists learn why patients with cystic fibrosis have less exercise capacity than their peers, even if their lungs are relatively healthy. [More]
Low dose of opioids including methadone effective for treatment of testosterone suppression

Low dose of opioids including methadone effective for treatment of testosterone suppression

Treatment for opioid addiction tampers with the testosterone levels of male but not female opioid users, McMaster University research has shown. [More]
Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. [More]